MacroGenics Expands ZYNYZ Royalty Agreement with Sagard Healthcare Partners for Cancer Drug

Key Takeaways

• MacroGenics expanded its existing ZYNYZ royalty purchase agreement with Sagard Healthcare Partners
• The deal provides MacroGenics with additional funding in exchange for capped royalty interest on future global sales
• ZYNYZ (retifanlimab-dlwr) is an antibody-based cancer immunotherapy in MacroGenics’ pipeline

---

MacroGenics Secures Additional Funding Through Expanded ZYNYZ Royalty Deal

MacroGenics, Inc. (Nasdaq: MGNX) announced on May 4, 2026, that it has entered into an expanded royalty purchase agreement with Sagard Healthcare Partners for its cancer immunotherapy ZYNYZ® (retifanlimab-dlwr). The Rockville, Maryland-based clinical-stage biopharmaceutical company will receive additional funding in exchange for providing Sagard with a capped royalty interest on future global net sales of the drug.

Building on Previous Partnership

This expanded agreement builds upon the initial ZYNYZ royalty purchase agreement that MacroGenics and Sagard first established in June 2025. The original deal demonstrated investor confidence in the commercial potential of ZYNYZ, an innovative antibody-based therapeutic designed for cancer treatment.

Strategic Financial Move for Cancer Drug Development

Royalty purchase agreements have become increasingly popular in the biopharmaceutical industry as they provide companies with immediate capital while allowing investors to participate in future drug revenues. For MacroGenics, this expanded agreement likely provides crucial funding to advance ZYNYZ through clinical development and potential commercialization.

ZYNYZ represents part of MacroGenics’ broader focus on developing innovative antibody-based therapeutics for cancer treatment. The company specializes in creating targeted immunotherapies that harness the body’s immune system to fight cancer cells.

Market Implications

The expansion of the royalty agreement suggests positive developments in ZYNYZ’s clinical progress or commercial prospects. Sagard Healthcare Partners, by increasing their investment, appears confident in the drug’s potential to generate significant future sales revenue.

This type of financing arrangement allows MacroGenics to maintain control over its drug development while securing necessary capital for operations, clinical trials, and potential market launch preparations.

---

Frequently Asked Questions

What is ZYNYZ and how does it treat cancer?

ZYNYZ (retifanlimab-dlwr) is an antibody-based immunotherapy drug developed by MacroGenics for cancer treatment. It works by targeting specific pathways to help the immune system fight cancer cells.

What does this royalty agreement mean for MacroGenics financially?

The expanded royalty agreement provides MacroGenics with additional upfront funding in exchange for giving Sagard a capped percentage of future ZYNYZ sales revenues, helping fund continued drug development.

When will ZYNYZ be available to patients?

MacroGenics has not announced specific timeline details for ZYNYZ availability. As a clinical-stage company, the drug is still undergoing development and regulatory review processes before potential market approval.

Related coverage

• FDA investigates Salmonella in moringa leaf powder, expands recall
• Breast Cancer Statistics Worldwide: What the Data Shows
• BioNTech doses first patient in Phase 1 pancreatic cancer mRNA vaccine trial